Axonics Inc (OQ:AXNX)

Mar 22, 2024 04:01 pm ET
Axonics Stockholders Approve Merger Agreement with Boston Scientific
Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independent inspector of election, will be reported on a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
Mar 21, 2024 04:54 pm ET
Axonics Provides Update on Inter Partes Review Proceedings
Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.
Mar 14, 2024 06:00 am ET
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.
Mar 02, 2024 10:45 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, AXNX, CPE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: M.D.C. Holdings, Inc. (NYSE: MDC)’s...
Mar 01, 2024 05:15 pm ET
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – KAMN, JNPR, INBX, AXNX
Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...
Feb 29, 2024 04:01 pm ET
Axonics Responds to ITC Action by Medtronic
Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a “patient programmer with automated MRI compatibility verification” for an implantable medical device.
Feb 28, 2024 04:01 pm ET
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2023.
Feb 28, 2024 12:00 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axonics, Inc. (NASDAQ: AXNX)’s sale to...
Feb 27, 2024 03:30 pm ET
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Feb 26, 2024 06:50 pm ET
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BATL, AVRO, AXNX, JNPR
NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
Feb 24, 2024 10:14 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, BATL, JNPR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axonics, Inc. (NASDAQ: AXNX)’s sale to...
Feb 23, 2024 05:06 pm ET
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – AXNX, JNPR, BATL, AVRO
Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...
Feb 17, 2024 12:22 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates PGTI, AXNX, AVRO, CTLT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc. (NYSE: PGTI)’s...
Feb 16, 2024 10:40 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, AXNX, BATL, APA
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 10, 2024 10:53 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, PGTI, EGLE, BBAI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axonics, Inc. (NASDAQ: AXNX)’s sale to...
Feb 06, 2024 09:32 am ET
INVESTIGATION ALERT: Halper Sadeh LLC Investigates AXNX, AMAM, FGH
NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 31, 2024 05:30 am ET
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.
Jan 29, 2024 10:02 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RYZB, FGH, AXNX, AMAM
NEW YORK, Jan. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 26, 2024 10:18 pm ET
AXONICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of  Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX).  Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 25, 2024 08:07 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VIA, FGH, AXNX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Via Renewables, Inc. (NASDAQ: VIA)’s...
Jan 24, 2024 05:17 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MDC, HARP, CVLY, AXNX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and...
Jan 23, 2024 01:45 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FGH, AMAM, AXNX
NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 19, 2024 08:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – GRCL, AXNX, HARP, CVLY
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Jan 17, 2024 12:00 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, AMAM, HARP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:         FG Group Holdings Inc. (NYSE:...
Jan 16, 2024 10:00 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 16, 2024 08:05 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 13, 2024 08:47 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates FGH, AXNX, HARP, AMAM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:       FG Group Holdings Inc. (NYSE:...
Jan 12, 2024 07:20 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger - GRCL, KRTX, AXNX, HA
NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 10, 2024 05:10 pm ET
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 10, 2024 02:07 pm ET
Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm
NEW YORK, Jan. 10, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 
Jan 09, 2024 05:31 pm ET
ALERT: Juan Monteverde Encourages the Shareholders of AXNX, BVH, GRCL, CVLY to Take Action
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Jan 08, 2024 08:21 pm ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX, EAR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Harpoon Therapeutics, Inc. (NASDAQ:...
Jan 08, 2024 05:31 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AX
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jan 08, 2024 03:55 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Axonics, Inc. (NASDAQ: AXNX) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $71.00 for each share of Axonics stock that they hold. The transaction is valued at approximately $3.7 billion and is expected to close in the first half of 2024.
Jan 08, 2024 10:36 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX
NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 08, 2024 09:57 am ET
Shareholder Alert: Ademi LLP investigates whether Axonics, Inc. has obtained a Fair Price in its transaction with Boston Scientific
MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Axonics (Nasdaq: AXNX) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific.
Jan 08, 2024 08:47 am ET
AXNX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Axonics to Boston Scientific
The law firm of Wohl & Fruchter LLP is investigating the fairness of the $71.00 per share in cash pursuant to which Axonics, Inc. (Nasdaq: AXNX) (“Axonics”) has agreed to be sold to Boston Scientific Corporation (“Boston Scientific”). The sales...
Jan 08, 2024 08:20 am ET
AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Axonics, Inc. (NASDAQ: AXNX) to Boston Scientific Corporation for $71.00 in cash per share is fair to Axonics shareholders.
Jan 08, 2024 07:00 am ET
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.
Jan 08, 2024 07:00 am ET
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023.
Jan 08, 2024 06:00 am ET
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction
Dec 27, 2023 04:01 pm ET
Axonics to Present at the J.P. Morgan Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.
Nov 06, 2023 12:00 pm ET
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum Disorder (ASD). With an unwavering commitment to addressing the monogenic origins of these conditions,...
Nov 01, 2023 06:00 am ET
Axonics to Participate in November Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November:
Oct 30, 2023 04:01 pm ET
Axonics Reports Third Quarter 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023.
Oct 02, 2023 06:00 am ET
Axonics to Report Third Quarter 2023 Financial Results on October 30
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30.
Aug 25, 2023 06:00 am ET
Axonics to Participate in September Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September:
Aug 21, 2023 06:00 am ET
Axonics Announces CFO Retirement and Appoints Successor
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2.
Jul 27, 2023 04:01 pm ET
Axonics Reports Second Quarter 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2023.
Jun 29, 2023 06:00 am ET
Axonics to Report Second Quarter 2023 Financial Results on July 27
Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 2Q23 registration.
May 01, 2023 04:01 pm ET
Axonics Reports First Quarter 2023 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2023.
Apr 25, 2023 06:00 am ET
Axonics to Participate in Upcoming Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences:
Apr 24, 2023 06:00 am ET
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics’ existing sacral neuromodulation (SNM) offering.
Apr 10, 2023 06:00 am ET
Axonics to Report First Quarter 2023 Financial Results on May 1
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1.
Mar 29, 2023 06:00 am ET
Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 2 on the Financial Times 2023 list of the fastest growing companies in the Americas. This follows the company’s No.
Mar 07, 2023 06:00 am ET
Axonics to Participate in the SUFU 2023 Winter Meeting
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2023 Winter Meeting, which is being held in Nashville from March 7-11.
Mar 01, 2023 04:01 pm ET
Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022.
Feb 08, 2023 04:30 pm ET
Axonics to Report Fourth Quarter 2022 Financial Results on March 1
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1.
Jan 31, 2023 06:00 am ET
Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system.
Jan 11, 2023 06:00 am ET
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance.
Dec 21, 2022 06:00 am ET
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Dec 13, 2022 06:00 am ET
Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Health Canada has approved the company’s fourth-generation rechargeable sacral neuromodulation system.
Nov 18, 2022 06:00 am ET
Axonics® to Participate in the Piper Sandler Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022.
Nov 16, 2022 11:06 am ET
Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 4 on the Deloitte Technology Fast 500, a
Oct 31, 2022 04:01 pm ET
Axonics® Reports Third Quarter 2022 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2022.
Sep 08, 2022 06:00 am ET
Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15™, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
Aug 18, 2022 06:00 am ET
Axonics® to Participate in September Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences:
Aug 17, 2022 06:00 am ET
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology.
Aug 05, 2022 04:34 pm ET
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock
Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the exercise in full by the underwriter of its option to purchase 262,500 additional shares. The gross proceeds from the offering to Axonics, before deducting estimated offering expenses, were approximately $128.5 million.
Aug 02, 2022 11:13 pm ET
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it priced its previously announced underwritten public offering of 1,750,000 shares of its common stock. The offering is expected to close on August 5, 2022, subject to the satisfaction of customary closing conditions.
Aug 02, 2022 04:11 pm ET
Axonics® Announces Proposed Public Offering of Common Stock
Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed underwritten public offering of 1,750,000 shares of its common stock. Axonics expects to grant the underwriter a 30-day option to purchase up to an additional 262,500 shares of its common stock.
Aug 01, 2022 04:01 pm ET
Axonics® Reports Second Quarter 2022 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2022.
Jul 11, 2022 06:00 am ET
Axonics® to Report Second Quarter 2022 Financial Results on August 1
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1.
May 31, 2022 06:00 am ET
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulation implantable neurostimulator (INS).
May 05, 2022 04:01 pm ET
Axonics® Reports First Quarter 2022 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022.
Apr 26, 2022 06:00 am ET
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022.
Apr 19, 2022 06:00 am ET
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system received FDA
Apr 14, 2022 04:01 pm ET
Axonics® to Report First Quarter 2022 Financial Results on May 5
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022.
Apr 04, 2022 06:00 am ET
Axonics® Launches Direct to Consumer Television Advertising Campaign
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign.
Mar 07, 2022 04:01 pm ET
Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS).
Feb 24, 2022 04:01 pm ET
Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2021.
Feb 03, 2022 06:00 am ET
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022.
Feb 01, 2022 06:00 am ET
Axonics® to Participate in SVB Leerink Virtual Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the SVB Leerink Virtual Healthcare Conference on February 17, 2022.
Jan 25, 2022 06:00 am ET
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence (UI) prevalence in the U.S.
Jan 06, 2022 06:00 am ET
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2021.
Nov 30, 2021 06:00 am ET
Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Raymond W. Cohen, chief executive officer of Axonics, has been awarded the 2021 Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council (SoCalBio).
Nov 17, 2021 06:00 am ET
Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 1 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences
Nov 17, 2021 04:01 am ET
Deloitte Unveils 2021 North America Technology Fast 500 Rankings
SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Deloitte today released its "North America Technology Fast 500," an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences, fintech, and energy tech sectors, now in its 27th year.
Nov 08, 2021 06:00 am ET
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2021.
Nov 04, 2021 04:01 pm ET
Axonics® Reports Third Quarter 2021 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the third quarter ended September 30, 2021.
Oct 26, 2021 06:00 am ET
Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has been named by the Orange County Business Journal as the fastest growing publicly traded company in Orange County.
Oct 07, 2021 07:00 am ET
Axonics® to Report Third Quarter 2021 Financial Results on November 4
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2021 financial results after the market closes on Thursday, November 4, 2021.
Sep 22, 2021 06:08 pm ET
Axonics® Provides Additional Update on Inter Partes Review Proceedings
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic patents that Axonics is contesting.
Sep 13, 2021 05:19 pm ET
Axonics® Announces Partial Decision on Inter Partes Review Proceedings
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three of the six Medtronic patents that Axonics is contesting.
Aug 27, 2021 06:00 am ET
Axonics® to Participate in Upcoming Investor Conferences
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management will present at the following virtual investor conferences:
Aug 05, 2021 04:01 pm ET
Axonics® Reports Second Quarter 2021 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021.
Jul 15, 2021 06:00 am ET
Axonics® Announces Appointment of Dr. Esteban López to its Board of Directors
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the appointment of Esteban López, M.D., MBA, to its board of directors, effective immediately.
Jul 14, 2021 08:00 am ET
BioLife Solutions Announces Changes to Board of Directors
BOTHELL, Wash., July 14, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced changes to its board of directors.
Jul 08, 2021 06:00 am ET
Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2021 financial results after the market closes on Thursday, August 5, 2021.
Jun 24, 2021 04:01 pm ET
Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation (SNM) implantable neurostimulator (INS).
May 20, 2021 06:00 am ET
Axonics® Receives FDA Approval Further Expanding MRI Labeling
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans.
May 18, 2021 09:00 am ET
Axonics® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval
Axonics previously received U.S. Food & Drug Administration approval for this INS and remote control during 2020. This version reduces how frequently a patient needs to recharge their sacral neuromodulation device to just once a month for about one hour. The newly approved remote control simplifies the process by which patients can receive a full-body MRI, avoiding the need for the patient to visit their implanting physician’s office.
May 14, 2021 04:05 pm ET
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,025,000 shares of common stock at the public offering price of $50.00 per share, which includes the exercise in full by the underwriters of the underwriters’ option to purchase 525,000 additional shares at the public offering price. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offerin
May 11, 2021 10:55 pm ET
Axonics® Announces Upsize and Pricing of Public Offering of Common Stock
Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 3,500,000 shares of its common stock at a public offering price of $50.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and offering expenses, are expected to be $175 million. In addition, the underwriters have a 30-day option to purchase up
May 11, 2021 04:17 pm ET
Axonics® Announces Proposed Public Offering of Common Stock
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $150,000,000 in shares of its common stock. Axonics expects to grant the underwriters a 30-day option to purchase up to $22,500,000 in additional shares of its common stock at the public offering price, less the underwriting discount and commissions.
May 06, 2021 04:01 pm ET
Axonics® Reports First Quarter 2021 Financial Results
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the first quarter ended March 31, 2021.
Apr 22, 2021 06:00 am ET
Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021.
Apr 15, 2021 06:00 am ET
Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2021 financial results after the market closes on Thursday, May 6, 2021.
Mar 03, 2021 06:00 am ET
Axonics® to Participate in the Barclays Global Healthcare Conference
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on March 10, 2021.
Mar 02, 2021 06:00 am ET
Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it has entered into a strategic alliance with Micro Systems Technologies (MST), a leading manufacturer of medical microelectronics.
Feb 25, 2021 04:05 pm ET
Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fiscal year ended December 31, 2020.
Feb 25, 2021 04:01 pm ET
Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has acquired privately-held Contura Ltd. and its flagship product, Bulkamid, a best-in-class urethral bulking agent for women with stress urinary incontinence (SUI).
Feb 22, 2021 04:01 pm ET
Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.
Feb 18, 2021 06:00 am ET
Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced it is participating as a platinum sponsor of the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2021 Winter Meeting, which is being held virtually from February 25-27.
Feb 16, 2021 06:00 am ET
Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration (FDA) for its third-generation implantable neurostimulator (INS).
Feb 11, 2021 06:00 am ET
Axonics® to Participate in the SVB Leerink Global Healthcare Conference
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Healthcare Conference on February 24, 2021.
Jan 25, 2021 04:01 pm ET
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2020.
Dec 14, 2020 08:00 am ET
Axonics® Announces Appointment of David M. Demski to Board of Directors
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021.
Nov 19, 2020 06:00 am ET
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1-2, 2020.
Nov 10, 2020 06:00 am ET
Axonics® Announces Publication of Fecal Incontinence Study Results for Patients Treated with r-SNM® System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the publication of fecal incontinence study results for patients treated with the Axonics r-SNM System.
Nov 04, 2020 04:00 pm ET
Axonics® Reports Third Quarter 2020 Results
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the third quarter 2020.
Oct 29, 2020 06:00 am ET
Axonics® Submits PMA Supplement to FDA to Further Expand MRI Labeling
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (PMA) supplement to the FDA for the purpose of gaining detachable extremity coil magnetic resonance imaging (MRI) conditional labeling for 1.5T and 3.0T MR scanners.
Oct 20, 2020 08:00 am ET
Axonics® Launches ARTISTRY Study to Collect and Analyze Real-World Data of Patients Implanted with the Axonics r-SNM System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has launched a new post-market clinical registry study to collect and analyze real-world data of patients treated with the Axonics r-SNM® System.
Oct 14, 2020 06:00 am ET
Axonics® to Report Third Quarter 2020 Results on November 4
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report third quarter 2020 financial results and provide an operational update after the market closes on Wednesday, November 4, 2020.
Oct 07, 2020 04:00 pm ET
Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Winner for Orange County
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, CEO of Axonics, has been named an Ernst & Young Entrepreneur of the Year 2020 Award winner for the Pacific Southwest, Orange County. The Entrepreneur of the Year program honors entrepreneurial business leaders whose vision fosters innovation, growth and prosperity as they build and sustain successful businesses. The award was announc
Oct 05, 2020 08:00 am ET
Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced survey results of 137 patients previously implanted with the Medtronic InterStim II™ that are now being treated with the Axonics r-SNM System.
Sep 24, 2020 06:00 am ET
 Axonics® Provides Update on Inter Partes Review Proceedings
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has made the decision to institute a review regarding the validity of six Medtronic patents that Axonics is contesting.
Sep 23, 2020 07:00 am ET
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date,...
Sep 21, 2020 06:00 am ET
Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Health Canada has approved its next generation rechargeable implantable neurostimulator (INS) for the Axonics r-SNM® System.
Sep 16, 2020 09:00 am ET
Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Finalist for Orange County
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, Axonics CEO, has been named an Ernst & Young Entrepreneur of the Year 2020 Award finalist for Orange County. The Entrepreneur of the Year program honors entrepreneurial business leaders whose vision fosters innovation, growth and prosperity as they build and sustain successful businesses.
Sep 10, 2020 06:00 am ET
Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has reported full 2-year clinical results from its ARTISAN-SNM pivotal study.
Sep 08, 2020 08:30 am ET
NICE Recommends Axonics® r-SNM System for Treating Overactive Bladder
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the publication of medical technologies guidance for the Axonics r-SNM System by the National Institute for Health and Care Excellence (NICE).
Sep 03, 2020 06:00 am ET
Axonics® to Participate in Upcoming Investor Conferences
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, CEO of Axonics, will participate in the following upcoming investor conferences:
Sep 02, 2020 10:00 am ET
Axonics® to Host Presentation of Full 2-Year Clinical Results from ARTISAN-SNM Pivotal Study on September 9
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will host a webinar on September 9 during which principal investigators of the ARTISAN-SNM pivotal study will present full 2-year clinical results.
Aug 06, 2020 04:00 pm ET
Axonics® Reports Second Quarter 2020 Results
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the second quarter 2020 and provided an update on operational initiatives.
Jul 27, 2020 06:00 am ET
Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced completion of 2-year follow-ups and topline clinical results from its ARTISAN-SNM pivotal study that was conducted to evaluate the safety and efficacy of the Axonics r-SNM System®.
Jul 16, 2020 06:00 am ET
Axonics® to Report Second Quarter 2020 Results on August 6
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report financial results for the second quarter of 2020 after the market closes on Thursday, August 6, 2020.
Jul 13, 2020 06:00 am ET
Axonics® Reports Preliminary Second Quarter 2020 Revenue
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited second quarter 2020 revenue and provided an operational update.
Jul 01, 2020 04:00 pm ET
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has received U.S. Food & Drug Administration (FDA) approval under a premarket approval supplement for 3T full-body magnetic resonance imaging (MRI) conditional labeling for the Axonics r-SNM System®.
Jun 03, 2020 06:00 am ET
Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced U.S. Food & Drug Administration (FDA) approval of its new wireless patient Remote Control with SmartMRI™ technology for the Axonics r-SNM® System under a premarket approval (PMA) supplement.
May 19, 2020 06:00 am ET
Axonics® ARTISAN Results Published Demonstrating Continued Therapy Response and Patient Satisfaction at 1-year
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the publication of the 1-year results from its ARTISAN-SNM study in the peer-reviewed journal Neurourology & Urodynamics (“NAU”)
May 12, 2020 04:05 pm ET
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,600,000 shares of common stock at the public offering price of $32.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters’ option to purchase up to an additional 600,000 shares of its common stock. The gross proceeds from the offering t
May 07, 2020 09:14 pm ET
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 4,000,000 shares of its common stock at a public offering price of $32.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to b
May 07, 2020 04:12 pm ET
Axonics® Announces Proposed Public Offering of Common Stock
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $100,000,000 in shares of its common stock. Axonics expects to grant the underwriters a 30-day option to purchase up to $15,000,000 in additional shares of its common stock at the public offering price, less the underwriting discount.
May 05, 2020 04:00 pm ET
Axonics® Reports First Quarter 2020 Results
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the first quarter 2020 and provided an update on operational initiatives.
May 04, 2020 06:00 am ET
Axonics® to Present at Upcoming Investor Conferences
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:
Apr 29, 2020 06:00 am ET
Axonics® Names Michael H. Carrel as Chairman of its Board of Directors
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today the appointment of Michael H. Carrel as chairman of the Axonics board of directors. Concurrent with this appointment, Raphael Wisniewski, who has served as chairman of Axonics since the Company’s inception in late 2013, is retiring and will not stand for re-election at the 2020 annual meeting of stockholders.
Apr 14, 2020 06:00 am ET
Axonics® Announces U.S. Food & Drug Administration Approval of Next Generation Implantable Neurostimulator
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approval of its next generation rechargeable implantable neurostimulator (“INS”) for its r-SNM® System under a premarket approval (“PMA”) supplement.
Apr 08, 2020 06:00 am ET
Axonics® to Present at the Needham Healthcare Conference
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a virtual fireside chat at the Needham Healthcare Conference on Wednesday, April 15 at 1:30pm ET and will be available for virtual meetings with institutional investors.
Apr 07, 2020 06:00 am ET
Axonics® to Report First Quarter 2020 Financial Results on May 5
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the first quarter of 2020 after the market closes on Tuesday, May 5, 2020.
Apr 06, 2020 06:00 am ET
Axonics® Submits PMA Supplement to U.S. Food & Drug Administration to Expand Full-Body MRI Labeling for 3T Scans
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of a premarket approval (“PMA”) supplement to the U.S. Food & Drug Administration (“FDA”) for the purpose of gaining full-body magnetic resonance imaging (“MRI”) conditional labeling for 3.0T MRI scans.
Mar 16, 2020 06:00 am ET
Axonics® Announces Filing of Petitions Before the United States Patent and Trademark Office Contesting the Validity of Medtronic Patents
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported that today the Company is filing seven petitions before the United States Patent and Trademark Office (“USPTO”) requesting inter partes review (“IPR”) to contest the validity of each of the patents Medtronic has alleged to be infringed by Axonics.
Mar 04, 2020 04:01 pm ET
Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter and year ended December 31, 2019 and provided an update on operational initiatives.
Feb 25, 2020 06:00 am ET
Axonics® to Present at the Barclays Global Healthcare Conference
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the Barclays Global Healthcare Conference, Tuesday, March 10 at 3:50pm ET in Miami Beach, FL, and will be available for meetings with institutional investors.
Feb 19, 2020 06:00 am ET
Axonics® to Report 2019 Fourth Quarter and Full-Year Financial Results and Host a Conference Call on March 4
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the 2019 fourth quarter and full year, and provide an update on U.S. launch activities after the market closes on Wednesday, March 4, 2020.
Feb 11, 2020 06:00 am ET
Axonics® to Present at the SVB Leerink Global Healthcare Conference
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference, Tuesday, February 25, at 3:30pm ET in New York City, and will be available for meetings with institutional investors.
Feb 04, 2020 06:00 am ET
Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that the German Institute for the Hospital Remuneration System (“InEK”) granted Status 1 reimbursement approval to the Axonics r-SNM® System under a New Examination and Treatment Method (“NUB”).
Jan 21, 2020 06:00 am ET
Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (SNM) devices for the treatment of bladder and bowel dysfunction, today announced U.S. Food & Drug Administration (“FDA”) approval of an enhanced, second-generation Programmer for its r-SNM® System under a premarket approval (“PMA”) application supplement.
Jan 09, 2020 06:00 am ET
Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited revenue of approximately $10 million for the fourth quarter of 2019 as compared to $0.5 million in the prior year period. For the full year ended December 31, 2019, unaudited revenue was approximately $14 million as compared to $0.7 million for all of 2018.
Dec 19, 2019 06:00 am ET
Axonics® Granted Six U.S. Patents and Allowed Three Additional Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that the United States Patent and Trademark Office has issued or allowed Axonics nine U.S. utility patents in 2019, along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.
Dec 12, 2019 06:00 am ET
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that the underwriters of its follow-on public offering exercised in full their option to purchase an additional 750,000 shares of common stock from Axonics at the offering price of $22.00 per share, less underwriting discounts and commissions.
Dec 09, 2019 06:00 am ET
Axonics® Provides Survey Results from Physician Seminar Series Showcasing the Recently FDA Approved Axonics r-SNM® System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced completion of a post-approval U.S. physician seminar series and the results of surveys collected from the attendees. Axonics sponsored five one-day Saturday seminars held over the past two months in Orlando, Irvine, Dallas, Boston and Atlanta.
Dec 02, 2019 06:00 am ET
Health Canada Approves Full-Body MRI Labeling for the Axonics® Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“r-SNM®”) devices for the treatment of bladder and bowel dysfunction, today announced Health Canada (Homologation d'un instrument medical) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 and 3 Tesla MRI scanners for patients implanted with the Axonics r-SNM System.
Nov 26, 2019 06:00 am ET
Axonics® to Present at Upcoming Investor Conferences
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:
Nov 25, 2019 06:00 am ET
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that surgeons have begun implanting commercial patients with the Axonics r-SNM® System at Sanford Health facilities (“Sanford”).
Nov 22, 2019 04:24 pm ET
Axonics® Announces Closing of $110 Million Public Offering of Common Stock
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 5,000,000 shares of common stock at the offering price of $22 per share. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $101 million. The offering consisted of 4,595,000 shares
Nov 21, 2019 06:00 am ET
Axonics® Announces Agreement to Supply its Sacral Neuromodulation System to The University of Tennessee Medical Center
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has entered into an agreement to supply the Axonics r-SNM® System to The University of Tennessee Medical Center (UTMC) in Knoxville, Tennessee.
Nov 19, 2019 09:15 pm ET
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 5,000,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to b
Nov 19, 2019 04:01 pm ET
Axonics® Announces Proposed Public Offering of Common Stock
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $110,000,000 in shares of its common stock. The offering is expected to consist of $100,000,000 of shares to be offered by Axonics and $10,000,000 of shares to be offered by selling stockholders. Axonics expects to grant the underwriters a 30-day option to purchase up to $16,500,000 i
Nov 14, 2019 04:00 pm ET
Axonics® Announces Third Quarter 2019 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the third quarter ended September 30, 2019, and provided an update on operational initiatives.
Nov 14, 2019 06:00 am ET
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications
The FDA premarket approval (“PMA”) grants Axonics the right to market its product in the United States for the clinical indications of OAB (urinary urge incontinence and urinary urge frequency) as well as urinary retention, representing the largest segment of the market for SNM devices. The FDA approval follows the Company’s September approval for the clinical indication of fecal incontinence, which, according to published clinical studies, is a co-morbidity reported by as many as a third of patients presenting with urinary urge incontinence.
Nov 07, 2019 06:00 am ET
Axonics® to Report 2019 Third Quarter and Nine-Month Financial Results and Host a Conference Call on November 14
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices, today announced that it will release financial results for the third quarter and first nine months of 2019, and provide an update on U.S. launch activities after the market closes on Thursday, November 14, 2019.
Nov 05, 2019 06:00 am ET
Axonics® Responds to Patent Action by Medtronic
Axonics has invested substantial time and resources in understanding the competitive landscape over the years since its inception in October 2013 and has been careful to respect the intellectual property rights of others in the design of its products, including the rights of Medtronic. Axonics is prepared to act quickly and defend itself aggressively and has already begun working with legal counsel. Beyond this, the need to protect the confidentiality of attorney communications limits what the Company can say about the specific allegations at this time.
Oct 15, 2019 06:00 am ET
Axonics® Provides Update on U.S. Launch Activities
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices, today provided an update on the status of U.S. launch activities following Food & Drug Administration (“FDA”) approval of the Axonics r-SNM® System for bowel dysfunction in September 2019.
Oct 07, 2019 06:00 am ET
Axonics® Broadens EU Commercial Footprint with Recommendation for Reimbursement in France and Supply Contract in Norway
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) system, today announced it achieved two milestones that expand its commercial reach in France and Norway. Specifically, the French Haute Autorité de Santé (“HAS”) published a positive recommendation required to gain reimbursement in France, and in Norway, a contract was awarded to supply the Axonics r-SNM® System to SNM-implanting hospitals in key cities.
Oct 03, 2019 06:00 am ET
Axonics® Provides Full One-Year Results from ARTISAN-SNM Pivotal Study at AUGS/IUGA Joint Scientific Meeting
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices, today announced the presentation of detailed one-year results from its ARTISAN-SNM pivotal study at a plenary session at the joint scientific meeting of the American Urogynecologic Society (AUGS) and the International Urogynecological Association (IUGA). The presentation of positive data, as well as numerous launch activities, highlighted Axonics’ first scientific meeting following the FDA clearance of the Axonics
Oct 02, 2019 06:00 am ET
Axonics® Announces Exclusive Agreement to Supply Sacral Neuromodulation Systems to Leading Urology Practice Group
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device, today announced that it has entered into an exclusive agreement to supply the Axonics r-SNM® System to Adult Pediatric Urology and Urogynecology (“ADPU”), headquartered in Omaha, Nebraska.
Sep 24, 2019 06:00 am ET
Axonics® to Exhibit its Sacral Neuromodulation System at the AUGS/IUGA Joint Scientific Meeting on September 24 – 28 in Nashville
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced it will exhibit its FDA approved1 r-SNM® System at the joint scientific mee
Sep 09, 2019 06:00 am ET
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced the approval of the Axonics r-SNM® System by the United States Food & Dr
Aug 27, 2019 06:00 am ET
Axonics® to Present at Upcoming Investor Conferences
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced that members of the senior management team will present at the following upcoming inv
Aug 05, 2019 04:00 pm ET
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, reported today financial results for the second quarter ended June 30, 2019, and provided an update on operational initiatives.
Aug 01, 2019 06:00 am ET
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced completion of 1-year follow-ups and top-line clinical results from its ARTISAN-SNM pi
Jul 29, 2019 06:00 am ET
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the results from its ARTISAN-SNM study were published online in the peer-revi
Jul 22, 2019 06:00 am ET
Axonics® to Report 2019 Second Quarter and Six-Month Financial Results and Host a Conference Call on August 5
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the second quarter a
Jun 18, 2019 06:00 am ET
Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“F
May 08, 2019 04:00 pm ET
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, reported today financial results for the first quarter ended March 31, 2019, and provided an update on operational initiatives.
May 06, 2019 09:00 am ET
Axonics® Announces ARTISAN-SNM Pivotal Study Results Presented at the American Urological Association Annual Meeting
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced the presentation of positive results from the
May 01, 2019 06:00 am ET
Axonics® to Present at Upcoming Investor Conferences
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that members of the senior management t
Apr 24, 2019 06:00 am ET
Axonics® to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results
Apr 08, 2019 09:00 am ET
Welkin Health Announces Partnership to Implement an Innovative Program to Support Commercialization of the Axonics® Cutting-Edge Sacral Neuromodulation Therapy
Welkin Health, a privately-held patient relationship management software company today announced it is partnering with
Apr 08, 2019 06:00 am ET
Axonics® Appoints Nancy L. Snyderman, M.D. and Jane E. Kiernan to its Board of Directors
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Nancy L. Snyderman, M.D. and Jane E
Apr 02, 2019 06:00 am ET
Axonics® to Present at the Needham Healthcare Conference
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that members of the management team wil
Mar 07, 2019 06:00 am ET
Axonics® to Participate in Upcoming Investor Events
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that members of the management team wil
Mar 05, 2019 04:00 pm ET
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter
Mar 04, 2019 06:00 am ET
Axonics® Appoints Michael H. Carrel to its Board of Directors
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Michael H. Carrel has been appointe
Feb 26, 2019 06:00 am ET
Axonics® Submits Pivotal Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of pivotal clinical data
Feb 22, 2019 11:30 am ET
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval f
Feb 19, 2019 06:00 am ET
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, disclosed today positive top-line results from the ARTIS
Feb 14, 2019 04:01 pm ET
Axonics® to Report 2018 Fourth Quarter and Full-Year Financial Results and Host a Conference Call on March 5
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results
Feb 12, 2019 06:00 am ET
Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of complete test data to

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More